Gilead Sciences (GILD)
Price: $45.99
Industry: Drugs Chaikin Power Gauge Report | Generated: Wed Feb 29 11:41 EST 2012 Power Gauge Rating
GILD - Bullish TM
The Chaikin Power Gauge Rating for GILD is bullish due to very bullish price/volume activity and strong earnings performance. Price and volume activity for GILD is very bullish which is indicated by positive Chaikin money flow and an increasing volume trend.
News Sentiment Rating
Bullish GILD Gilead Scien..
February 24, 2012
TM
Chaikin Sentiment Gauge for GILD is bullish. There is currently a significant positive sentiment within news stories concerning GILD.
News Sentiment :Positive
Power Trend - 5 Year Chart
The Power Gauge distills a 20 factor model into a concise picture of a stock's potential.
I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here
High Potential
Neutral
Low Potential
www.chaikinpowertools.com
Financials & Earnings
Financial Metrics Rating
Financial Metrics
Neutral
LT Debt/Equity Ratio
GILD's financial metrics are neutral. The company yields a high return on shareholder's equity and is carrying too much long term debt relative to its industry group.
Price to Book Value
Return on Equity
The rank is based on a high long term debt to equity ratio relative to its industry group, high price to book value ratio, high return on equity and relatively high cash flow.
Price to Sales Ratio
Business Value
Assets and Liabilities
Valuation
Returns
Ratio
TTM
Ratio
TTM
Ratio
Current Ratio
5.53
Price/Book
5.03
Return on Invest
25.6%
LT Debt/Equity
1.13
Price/Sales
4.12
Return on Equity
45.4%
Earnings Performance
TTM
Earnings Performance Rating
Bullish
Earnings Growth
GILD's earnings performance has been strong. The company is priced relatively low compared to next year's projected EPS and has a stable 5 year earnings trend.
Earnings Surprise
Earnings Trend
The rank is based on worse than expected earnings in recent quarters, a relatively low projected P/E ratio and consistent earnings over the past 5 years.
Projected P/E Ratio
Earnings Consistency
5 Year Revenue and Earnings Growth
Revenue(M) Rev % Growth EPS EPS % Growth
EPS Estimates
12/07
12/08
12/09
12/10
12/11
4,230.04
5,335.75
7,011.38
7,949.42
8,385.38
39.78%
26.14%
31.40%
13.38%
5.48%
$1.74
$2.18
$2.91
$3.39
$3.62
234.36%
25.29%
33.49%
16.49%
6.78%
EPS Surprise
Factor
Actual EPS Prev
EST EPS Current
Change
$0.82
$0.92
+0.10
Quarterly EPS Yearly EPS Factor
$3.62
$3.68
+0.06
Actual EPS Growth
Est EPS Growth
Change
23.24%
14.57%
-8.67
3-5 year EPS
EPS Quarterly Results Estimate
Actual
Difference
% Difference
FY
Qtr 1
Qtr 2
Qtr 3
Qtr 4
Total
Latest Qtr
$1.00
$0.92
$-0.08
1 Qtr Ago
$0.96
$0.97
$0.01
-8.00
12/09
$0.65
$0.63
$0.75
$0.89
$2.92
1.04
12/10
$0.95
$0.81
$0.85
$0.78
$3.39
2 Qtr Ago
$0.96
$0.95
3 Qtr Ago
$0.92
$0.82
$-0.01
-1.04
12/11
$0.82
$0.95
$0.97
$0.88
$3.62
$-0.10
-10.87
Fiscal Year End Month is December.
I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here
www.chaikinpowertools.com
Price Trend & Expert Opinions Price/Volume Activity
Price/Volume Activity Rating
Very Bullish
Relative Strength vs Market
Price and volume activity for GILD is very bullish. GILD is experiencing sustained buying and is trading on higher volume than its 90 day average volume.
Chaikin Money Flow
Price Trend
The rank for GILD is based on positive Chaikin money flow, a negative Chaikin price trend ROC and an increasing volume trend.
Price Trend ROC
Volume Trend
Relative Strength vs S&P500 Index
Chaikin Money Flow
Chart shows whether GILD is performing better or worse than the market.
Chaikin Money Flow analyzes supply and demand for a company's stock.
Price Activity
Price Activity
Volume Activity
Factor
Value
Factor
52 Week High
56.02
% Change Price - 4 Weeks
-5.85%
Average Volume 20 Days
13,973,421
52 Week Low
35.34
% Change Price - 24 Weeks
20.39%
Average Volume 90 Days
10,207,012
% Change Price - 4 Wks Rel to S&P
-9.95%
Chaikin Money Flow Persistency
% Change Price - 24 Wks Rel to S&P
2.90%
% Change YTD Rel S&P 500
1.82%
Expert Opinions
Value
Factor
Value
91%
Expert Opinions
Neutral
Earnings Estimate Revisions
Expert opinions about GILD are neutral. Analysts's opinions on GILD have been more positive recently and analysts are lowering their EPS estimates for GILD.
Short Interest
Insider Activity
The rank for GILD is based on analysts revising earnings estimates downward, a low short interest ratio, insiders purchasing stock and optimistic analyst opinions.
Analyst Opinions
Relative Strength vs Industry
Earnings Estimate Revisions Current Current Qtr Next Qtr
0.92 0.92 Current
Current FY
3.68
Analyst Recommendations
7 Days Ago % Change 0.92 0.92
0.00% 0.00%
30 Days Ago % Change 3.94
-0.26
EPS Estimates Revision Summary
Factor
Value
Mean this Week Mean Last Week
Strong Buy +0.08
Last 4 Weeks
Down
Up
Down
Curr Qtr
0
0
0
2
Curr Yr
0
0
1
5
Next Qtr
0
0
0
2
Next Yr
0
0
0
6
Buy
Change Mean 5 Weeks Ago
Last Week Up
Strong Buy
I want to receive special offers about trading stocks with your brokerage partner, optionsXpress. Click here
www.chaikinpowertools.com
The Company & Its Competitors
News Headlines for GILD
GILD's Competitors in Drugs Company
Power Gauge
Historic EPS growth
Projected EPS growth
Profit Margin
PEG
PE
Revenue(M)
23.24%
14.57%
33.44%
0.86
12.57
8,385
AMGN
1.80%
9.40%
23.64%
1.22
13.01
15,582
CELG
40.88%
22.74%
27.22%
0.74
21.50
4,842
VRTX
172.54%
-
2.10%
-
-
1,411
13.80%
13.05%
24.45%
1.46
19.98
5,049
-29.67%
-
-1050.95%
-
-
9,565
GILD
BIIB SVNT
U.S. FDA Grants Priority Review for TruvadaŽ for Reducing the Risk of Acquiring HIV Infection - Feb 13, 2012 Gilead Sciences jumps on hepatitis C data - Feb 3, 2012 Aptalis Pharma Announces FDA Approval of NDA for Oral Powder Form - Jan 18, 2012 Gilead Sciences Completes Acquisition of Pharmasset, In - Jan 17, 2012 Gilead nears completion of Pharmasset deal Jan 12, 2012
Company Details
Company Profile
Gilead Sciences 333 LAKESIDE DR FOSTER CITY, CA 94404 USA Phone: 6505743000 Fax: 650-578-9264 Website: http://http://www.gilead.com Full Time Employees: 4,000 Sector: Medical
Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.
Power Gauge Ratings are created using a relative ranking system that assigns a rank of 0 to 100 (100 being the highest) to each stock in the universe. Rank is calculated by evaluating each of the stocks factors and combining them into a single number using a weighting formula. A stock's rank ranges from 100-0, where 100 is the strongest, and a rank of 95 indicates the stock is better than 95% of the stocks in the universe. Chaikin Stock Research(CSR) is not registered as a securities broker dealer or investment advisor with either the U.S. Securities and Exchange Commission or with any state securities regulatory authority. CSR is not responsible for trades executed by users of this research report, our web site or mobile app based on the information included herein. The information presented in this report does not represent a recommendation to buy or sell stocks or any financial instrument nor is it intended as an endorsement of any security or investment. The information in this report is generic by nature and is not personalized to the specific financial situation of any individual. The user bears complete responsibility for their own investment research and should seek the advice of a qualified investment professional before making any investment decisions. Copyright (c) 1978-(Present) by ZACKS Investment Research, Inc ("ZACKS"). The information, data, analyses and opinions contained herein (1) includes the confidential and proprietary information of ZACKS, (2) may not be copied or redistributed, for any purpose, (3) does not constitute investment advice offered by ZACKS, (4) are provided solely for informational purposes, and (5) are not warranted or represented to be correct, complete, accurate or timely. ZACKS shall not be responsible for investment decisions, damages or other losses resulting from, or related to, use of this information, data, analyses or opinions. Past performance is no guarantee of future performance. ZACKS is not affiliated with Chaikin Power Tools. This report from Chaikin Power Tools is for informational purposes only and is not a recommendation to buy or sell securities.
LM 2.3 DS 3.0 LS 2.1
Data Provided by ZACKS Investment Research, Inc., www.zacks.com
Special offers to trade stocks from optionsXpress: www.chaikinpowertools.com